Skip to Content
Søg Menu

ASCO20: Why has non-metastatic castration-resistant prostate cancer become interesting?

Listen to Eric J. Small, MD and principal investigator of the SPARTAN study, explain why non-metastatic castration-resistant prostate cancer (nmCRPC) has become relevant. The SPARTAN study has investigated the efficiency and safety of apalutamide for patients with nmCRPC.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
ASCO20Prostatacancer

ASCO20: Key takeways from ASCO20 Virtual in prostate cancer

/ Eric J. Small
ASCO20Prostatacancer Play the Video 2:23

ASCO20: Patients with non metastatic castration resistant prostate cancer

/ Eric J. Small
ASCO20Prostatacancer Play the Video 2:03

ASCO20: Can you describe what characterizes the group of patients with non-metastatic castration-resistant prostate cancer?

/ Eric J. Small
ASCO20Prostatacancer Play the Video 5:49

ASCO20: How does early treatment influence the sequence of the following treatment if the disease progresses?

/ Eric J. Small
ASCO20Prostatacancer Play the Video 0:58

ASCO20: What are the key clinical messages from the SPARTAN study?

/ Eric Small
ASCO20Prostatacancer Play the Video 4:09

ASCO20: What was the background and study design of the SPARTAN study?

/ Eric Small
ASCO20Prostatacancer Play the Video 3:14
Back to top